TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 342319
Drug: 7 log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 log EID50/dose (twice vaccinated)
Study: 342319
Drug: 6 log
Normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 log EID50/dose (twice vaccinated)
Study: 31043770
Drug: 0.5 µg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/mL dexmedetomidine with 0.1% ropivacaine
Study: 31043770
Drug: 0.5 µg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/mL sufentanil with 0.1% ropivacaine
Study: 21697824
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor blockade (sulpiride (SULP) 400 mg)
Study: 19681862
Drug: R-salbutamol cream
Normalized name: (R)-salbutamol
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-salbutamol cream 0.5%
Study: 3288523
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily for under 5-year-olds, 2 mg twice daily for others)
Study: 31856493
Drug: Subthreshold micropulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthreshold micropulse yellow laser (SMYL) and intravitreal aflibercept injection (IAI) combination therapy
Study: 31856493
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) monotherapy
Study: 20171080
Drug: Intrathecal magnesium
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal magnesium sulphate 50 mg
Study: 20171080
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL of 0.9% sodium chloride (control group)
Study: 18074471
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (ivIgG) 0.6 g/kg body weight on day 0 and 0.3 g/kg body weight on day 1
Study: 18074471
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin G (ivIgG)
Study: 16214045
Drug: Oral tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral tegafur (FT) 750 mg/m2/day for 21 days and leucovorin (LV) 15 mg/m2 every 8 h in cycles repeated every 28 days
Study: 16214045
Drug: Intravenous leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous leucovorin (LV) 20 mg/m2 followed by 5-fluorouracil (5-FU) 425 mg/m2 daily for 5 days every 4 weeks for 2 cycles, and later every 5 weeks
Study: 9972958
Drug: Insulin induced
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin induced hypoglycemia
Study: 9972958
Drug: Thyrotropin releasing
Normalized name: Thyrotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin releasing hormone (TRH) stimulation
Study: 7751513
Drug: Inhaled lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lysine acetylsalicylate and furosemide (720 mg lysine acetylsalicylate and 40 mg furosemide twice daily)
Study: 12682418
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (400 IU daily)
Study: 6871066
Drug: Fenoctimine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoctimine 50 mg
Study: 6871066
Drug: Fenoctimine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoctimine 150 mg
Study: 6871066
Drug: Fenoctimine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoctimine 250 mg
Study: 23257991
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml kg(‐1) h(‐1) lactated Ringer's solution
Study: 23257991
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml kg(‐1) h(‐1) lactated Ringer's solution
Study: 15324520
Drug: CIP/DEX (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIP/DEX (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension, 3-4 drops twice daily for 7 days
Study: 15324520
Drug: N/P/H (neomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/P/H (neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0%) otic suspension, 3-4 drops three times daily for 7 days
Study: 10908255
Drug: BQ‐123 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ‐123 (a selective ET(A) receptor antagonist; 100 nmol/min) in 0.9% saline, infused into the left coronary artery at a rate of 1 ml/min for 60 minutes
Study: 9302398
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administration (12.5 or 18 micrograms/kg/day)
Study: 8094768
Drug: recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant tissue plasminogen activator (alteplase, rt-PA) 100 mg over 2 h followed by intravenous heparin
Study: 30940404
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20,000 IU of cholecalciferol once weekly for 24 weeks)
Study: 29797911
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with ibuprofen, methotrexate, and folic acid
Study: 29797911
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment with ibuprofen, methotrexate, and folic acid
Study: 27533265
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy for upper limbs
Study: 27533265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no supervised physical therapy)
Study: 18924018
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg daily for one week
Study: 16424704
Drug: High-dose antithrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antithrombin III (30,000 IU intravenously over 4 days)
Study: 12661672
Drug: Auditory modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory modality verification (e.g., BLENDER-loud)
Study: 12661672
Drug: Same modality
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same modality verification (e.g., LEAVES-rustling)
Study: 12661672
Drug: Different modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different modality verification (e.g., CRANBERRIES-tart)
Study: 17225476
Drug: Zolpidem 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 20 mg (Zol-20)
Study: 17225476
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (Zol-10)
Study: 17225476
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg (Mel-5)
Study: 17225476
Drug: Melatonin 10
Normalized name: melatonin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 10 mg (Mel-10)
Study: 15771635
Drug: Low-dose ERT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ERT (CEE 0.3125 mg/day) + SSRI (fluvoxamine 50 mg/day) for 8 weeks
Study: 15771635
Drug: Low-dose ERT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ERT (CEE 0.3125 mg/day) for 8 weeks
Study: 9690334
Drug: Usual-care antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-care antipsychotic medication
Study: 201958
Drug: Equine conjugated
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equine conjugated oestrogens tablets (Premarin)
Study: 23917775
Drug: Synthetic bacterial
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic bacterial lipoprotein and TLR1/2 agonist Pam(3)CSK(4) (BLP)
Study: 16807414
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose N-acetylcysteine (600 mg IV bolus before angioplasty and 600 mg orally twice daily for 48 hours after angioplasty)
Study: 16807414
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose N-acetylcysteine (1200 mg IV bolus and 1200 mg orally twice daily for 48 hours after intervention)
Study: 16807414
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose N-acetylcysteine
Study: 16807414
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose N-acetylcysteine
Study: 16807414
Drug: Composite endpoint
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite endpoint (death, acute renal failure requiring temporary renal-replacement therapy, or need for mechanical ventilation)
Study: 12681523
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose modafinil (200 mg/day)
Study: 12681523
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose modafinil (400 mg/day)
Study: 9243352
Drug: Intravenous selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous selegiline (0.5 mg)
Study: 9243352
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline (0.5 mg)
Study: 9243352
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline (1.0 mg)
Study: 9243352
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline (1.5 mg)
Study: 9243352
Drug: Oral selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selegiline (5 mg)
Study: 8491244
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg, administered orally once 12 hours before and once 12 hours after surgery
Study: 2116312
Drug: Meptazinol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (loading dose 50 mg followed by i.v. infusion 0.5 mg.kg‐1.h‐1)
Study: 2116312
Drug: Morphine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (loading dose 5 mg followed by i.v. infusion 0.05 mg.kg‐1.h‐1)
Study: 24247559
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + capecitabine (maintenance therapy)
Study: 24247559
Drug: Bevacizumab +
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab + XELOX (induction therapy until progression)
Study: 19583070
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (loading dose of 1 microg/kg over 10 min and maintenance dose of 0.5 microg/kg/hr)
Study: 12711925
Drug: Alcohol consumption
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol consumption (exact dosage and duration not specified)
Study: 10229979
Drug: Sterile sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile sea water spray
Study: 10229979
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without douche)
Study: 1679517
Drug: beta1-selective blockers
Normalized name: beta-Arbutin
DrugBank: Arbutin (DB11217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: beta1-selective blockers
Study: 1679517
Drug: nonselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonselective beta-blockers
Study: 7051761
Drug: Sulfaisodimidine 1
Normalized name: sulfaisodimidine
DrugBank: Sulfaisodimidine (DB13283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfaisodimidine 1 g four times daily (Group I)
Study: 7051761
Drug: Sulfaisodimidine 2
Normalized name: sulfaisodimidine
DrugBank: Sulfaisodimidine (DB13283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfaisodimidine 2 g twice daily (Group II)
Study: 30455335
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy after severe hypoglycemia
Study: 23312435
Drug: Maintenance cognitive
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance cognitive therapy (MCT)
Study: 21261433
Drug: Brief Strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Strategic Family Therapy
Study: 19697822
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg(‐1) rocuronium (group E)
Study: 19697822
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg(‐1) cis‐atracurium (group N)
Study: 19697822
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg kg(‐1) suxamethonium (group P)
Study: 9361690
Drug: Pirenzepine (PZP)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZP) 100 mg orally
Study: 1315100
Drug: Incision plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision plus curettage and primary suture under antibiotic (Clindamycin) cover
Study: 3883264
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg administered one hour before and again four and eight hours after abortion
Study: 29106076
Drug: TXA (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (1.0 g)
Study: 18537053
Drug: L-arginine application
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine application
Study: 17143986
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment plus usual care
Study: 10929922
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to loratadine after initial therapy with fexofenadine
Study: 10929922
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to fexofenadine after initial therapy with loratadine
Study: 3535757
Drug: Fenofibrate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (100 mg three times daily)
Study: 27184170
Drug: Alirocumab 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 50 mg
Study: 25068344
Drug: Autologous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fat injection (group A)
Study: 25068344
Drug: Autologous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fat injection with plasma rich in growth factors (group B)
Study: 20087330
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg) enema treatment once daily for 14 days
Study: 20087330
Drug: Mesalazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (1 g) enema treatment once daily for 14 days
Study: 8192751
Drug: High ratio
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High ratio of immune complex-dissociated to native antibody titer
Study: 8192751
Drug: Native antibody
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native antibody titers
Study: 27855365
Drug: RFA (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFA (in 8 patients with CEA > 50 ng/mL)
Study: 27855365
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell therapy (in 8 patients with CEA > 50 ng/mL)
Study: 18949289
Drug: Propolis orabase
Normalized name: ORABASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis orabase gel (PRO)
Study: 18949289
Drug: Orabase gel
Normalized name: Orabase Gel-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orabase gel without active component (Control)
Study: 10084271
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily (add-on therapy to timolol)
Study: 10084271
Drug: Pilocarpine 2%
Normalized name: PILOCARPINE 2% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine 2% three times daily (add-on therapy to timolol)
Study: 10084271
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily (switch from timolol)
Study: 8747987
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HD-CY) or dose-escalated ifosfamide/mitoxantrone followed by filgrastim (R-metHuG-CSF, 300 micrograms/day)
Study: 8747987
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose treatment
Study: 1905614
Drug: Etidronate disodium
Normalized name: Etidronate Disodium
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate disodium (Didronel; 750 mg orally daily)
Study: 31046082
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A)
Study: 31046082
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort B)
Study: 31046082
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg administered intravenously every 3 weeks until cancer progression, toxicity, or completion of 2 years (Cohort A and B)
Study: 18640457
Drug: Dimebon (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimebon (60 mg/day, 20 mg three times a day)
Study: 12133397
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg + MPA 2 mg + Ca-D 1 tablet daily (Group A)
Study: 12133397
Drug: CEE 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.3 mg + MPA 2 mg + Ca-D 1 tablet daily (Group B)
Study: 12133397
Drug: Cal-D 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal-D 1 tablet daily alone (Group C)
Study: 10394089
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 5 mg (n = 6)
Study: 10394089
Drug: Naloxone 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 2.4 mg (n = 6)
Study: 2202773
Drug: Erythromycin Base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin Base Filmtab (nonenteric-coated) at 1 g/d
Study: 2202773
Drug: Erythromycin Base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin Base Filmtab (nonenteric-coated) at 2 g/d
Study: 2202773
Drug: Eryc (enteric-coated)
Normalized name: Erycibe obtusifolia stem extract
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eryc (enteric-coated) at 1 g/d
Study: 2202773
Drug: Eryc (enteric-coated)
Normalized name: Erycibe obtusifolia stem extract
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eryc (enteric-coated) at 2 g/d
Study: 45211
Drug: IV almitrine
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV almitrine 0.5 mg/kg
Study: 26189067
Drug: Investigational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational group (oxaliplatin + leucovorin + fluorouracil during adjuvant chemotherapy)
Study: 26189067
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fluorouracil + leucovorin during adjuvant chemotherapy)
Study: 26189067
Drug: Investigational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational group (preoperative and postoperative treatment)
Study: 26189067
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (preoperative and postoperative treatment)
Study: 15308586
Drug: Tomato oleoresin
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato oleoresin extract (3 capsules daily for 2 weeks, each containing 4.88 mg lycopene, 0.48 mg phytoene, 0.44 mg phytofluene, and 1.181 mg alpha-tocopherol)
Study: 11160057
Drug: L‐NMMA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (10 mg)
Study: 11160057
Drug: L‐arginine (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐arginine (375 mg)
Study: 11160057
Drug: L‐NMMA vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA vs L‐arginine
Study: 11160057
Drug: L‐NMMA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA and L‐arginine
Study: 9748428
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 1000 microgram administered twice daily at 08:00 h and 20:00 h
Study: 8046314
Drug: Pirprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (400 mg t.i.d.)
Study: 24905321
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 2.5 mg
Study: 24905321
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 5 mg
Study: 24905321
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 10 mg
Study: 24905321
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride (all doses)
Study: 23536652
Drug: Ribavirin monotherapy
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin monotherapy for 6 weeks
Study: 12668582
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid (375, 500, or 625 mg)